Weekly Roundup: September 21-25

September 25, 2020

ICYMI, some of the content featured this week includes articles about how to choose a telemedicine vendor, the launch of an international COVID-19 dermatology registry, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, plus more.

In case you missed it, some of this week’s featured content includes articles about the launch of an international COVID-19 dermatology registry by the American Academy of Dermatology’s (AAD) COVID-19 Task Force, how to choose a telemedicine vendor, a new vitiligo repigmentation study, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) accepting marketing applications for bimekizumab as a treatment for plaque psoriasis, plus more.

Dupilumab outlasts cyclosporine

Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.

Selling your practice: Solicit a letter of intent, negotiate material terms of sale

In this month's article on Selling Your Practice, we discuss letter of intent (LOI), soliciting letter(s) of intent, and negotiating the material terms for a sale of your practice.

The Mainstream Patient: September 21

This week’s edition of The Mainstream Patient features stories about dark circles, sun damage on different skin tones, wearing sunscreen with a mask, sleep’s effect on skin health, plus more.

FDA, EMA accepts marketing applications for bimekizumab in psoriasis

UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.

How to choose a telemedicine vendor

With the increase in telemedicine use, physicians can (virtually) meet their patients’ needs now more than ever. However, with this swift increase in telehealth usage, how can physicians choose the best telemedicine vendor for their practice with so many options available?

First patient enrolled in vitiligo repigmentation study

AVITA Therapeutics has launched a study evaluating their RECELL System as a treatment for stable vitiligo.

Identifying dermatologic conditions in pediatric patients with COVID-19

A recent article suggests physicians should be on the lookout for various dermatologic manifestations in pediatric patients suspected of having COVID-19.

Cross-specialty collaboration key to tracking COVID-19 skin symptoms

Esther Freeman, M.D., details the team effort made by the American Academy of Dermatology’s (AAD) COVID-19 Task Force to launch an international registry documenting skin manifestations in patients diagnosed with or suspected of COVID-19 infection.

Picosecond laser evaluated in melasma study

A study published by the American Society of Laser Medicine and Surgery reveals the efficacy of the 755-nm picosecond laser as a treatment for melasma in Asian women with darker skin types.

AAD, NPF guidelines urge liver disease monitoring in psoriasis patients

The latest guidelines for psoriasis from the American Academy of Dermatology and the National Psoriasis Foundation recommend physicians monitor their patients for liver disease when prescribed medication for psoriasis, such as methotrexate.